| abstract |
The present invention relates to a bilayer tablet comprising the system classification name (3R, 5S, 6E)-7-[4-(4-fluorophenyl)-2-(N-methylmethanesulfonylamino)- Rosuvastatin of the formula I, 6-(propan-2-yl)pyrimidin-5-yl]-3,5-dihydroxyhept-6-enoic acid, or a pharmaceutically acceptable salt, ester or hydrate thereof Or solvate, and the system is classified as (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl] Ezetimibe of formula II of -4-(4-hydroxyphenyl)azetidin-2-one or two of its pharmaceutically acceptable salts, esters, hydrates or solvates The different active ingredients, together with suitable pharmaceutically acceptable excipients, are in the form of a circular bilayer tablet. This composition has excellent properties in terms of its physical properties and release rate of the active material or product stability. |